Disclosed herein are methods and compositions for treating multiple myeloma, and for enhancing antibody-dependent cellular toxicity (ADCC). Specifically, disclosed herein are methods of using antagonists of the aryl hydrocarbon receptor (AHR) to treat multiple myeloma and enhance ADCC. Also specifically disclosed is liposomal CH233191.